CCL22 is a biomarker of severe COVID-19; CCL22 controls immunity by promoting the communication of regulatory T cells to dendritic cells, which is essential for recruiting Th2 cells in the respiratory tissues [105]. This evidence concerns the gene CCL22 and COVID-19.